GlassScriptPhysician profile
Paul Weissblatt
NPI 1619274172
$3,334.26
in general payments reported to CMS, 2019-2025
25 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $515 · 2023: $853 · 2024: $876 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,277.25 | 2022-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $339.16 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Genzyme Corporation | $292.66 | 2022-2025 | |
| Axonics, INC. | $185.18 | 2023-2024 | Axonics |
| Pfizer INC. | $153.37 | 2023-2025 | |
| Ardelyx, INC. | $144.94 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $130.82 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $127.42 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.68 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $84.82 | 2023-2024 | Omvoh |
| Aimmune Therapeutics, INC. | $69.67 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $66.78 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $46.56 | 2022-2024 | Zeposia |
| Novo Nordisk INC | $44.90 | 2025 | Wegovy |
| Celgene Corporation | $42.50 | 2022-2023 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $35.86 | 2025 | |
| Madrigal Pharmaceuticals | $31.28 | 2025 | Rezdiffra |
| Capsovision, INC. | $26.08 | 2025 | Capsocam Plus |
| Biocon Biologics INC | $24.99 | 2025 | Yesintek |
| Celltrion USA INC. | $22.05 | 2024 | Vegzelma |
| Boston Scientific Corporation | $21.42 | 2025 | Axonics |
| Gilead Sciences, INC. | $20.66 | 2023 | |
| Redhill Biopharma INC. | $20.18 | 2022 | |
| Intercept Pharmaceuticals, INC. | $19.09 | 2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Weissblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.